Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
$27.49
-$0.03(-0.09%)
At close: 4:00 PM EST
$27.49
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $62.45
Previous CloseN/A
Volume212.48K
Average Volume (3M)1.73M
Market Cap
$1.57B
Enterprise Value$1.43B
Total Cash (Recent Filing)$952.86M
Total Debt (Recent Filing)$44.52M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Feb 12, 2026EPS Estimate
-1.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding58,313,812
10 Day Avg. Volume3,995,514
30 Day Avg. Volume1,733,640
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.21
Price to Sales (P/S)51.14
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue31.82
Enterprise Value/Gross Profit37.70
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$32.13Price Target Upside16.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-7.04
Revenue Forecast (FY)$45.99M
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe trial successfully met the primary endpoint of hemoglobin response in 40.6% of patients compared to 2.9% in the placebo group.
Market OpportunitySignificant opportunity for value creation in thalassemia, with positive recent labeling discussions with the FDA.
Regulatory ApprovalFDA approval of Pyrukynd in thalassemia is likely, with a high probability of approval, and strong physician adoption is anticipated given limited treatment options for thalassemia.
Bears Say
Regulatory ChallengesThe requirement for a REMS to address potential liver injury risk could impact the launch of Pyrukynd in thalassemia.
Stock Price TargetThe Dec 2026 price target has been lowered to $20 from $37 following top-line results from the phase 3 RISE UP trial for Pyrukynd in sickle cell disease.
Trial OutcomeThe trial did not meet the primary endpoint of reducing the annualized rate of sickle cell pain crises significantly.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $22.24 and its highest was $62.45 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.57B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Feb 12, 2026 which is in 69 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Oct 30, 2025. The company reported -$1.78 earnings per share for the quarter, beating the consensus estimate of -$1.897 by $0.117.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.95.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 58,313,812 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.78 in its last earnings report, beating expectations of -$1.897. Following the earnings report the stock price went up 2.908%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.13 (16.88% Upside)
$32.13 (16.88% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 183.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $315.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.12%
12-Months-Change
Fundamentals
Return on Equity
-27.57%
Trailing 12-Months
Asset Growth
-22.66%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. (AGIO) is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancer and rare genetic diseases. The company operates primarily in the oncology and rare disease sectors, leveraging its expertise in metabolic pathways to develop targeted therapies. Agios is known for its proprietary drugs such as IDHIFA (enasidenib) and TIBSOVO (ivosidenib), which are designed to treat specific forms of cancer related to isocitrate dehydrogenase (IDH) mutations.
AGIO Company Deck
AGIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance, global regulatory progress, and significant pipeline advancements. However, there are challenges with increased expenses and potential regulatory hurdles related to the REMS program.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$32.13
▲(16.88% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
Currently, No data available
---